Asset Publisher

ph-1129

print Print Back Back

Copay Waiver for Human Immunodeficiency Virus (HIV) Infection: Pre-exposure Prophylaxis (PrEP) ACA Prevention Copay Waiver Program Summary – Individual Marketplace, Commercial

Policy Number: PH-1129

POLICY REVIEW CYCLE

Effective Date

Date of Origin   

07-01-2024           

07-01-2020

This pharmacy policy is not an authorization, certification, explanation of benefits or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member’s plan in effect as of the date services are rendered. All pharmacy policies are based on (i) information in FDA approved package inserts (and black box warning, alerts, or other information disseminated by the FDA as applicable); (ii) research of current medical and pharmacy literature; and/or (iii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment. 

The purpose of Blue Cross and Blue Shield of Alabama’s pharmacy policies are to provide a guide to coverage. Pharmacy policies are not intended to dictate to physicians how to practice medicine. Physicians should exercise their medical judgment in providing the care they feel is most appropriate for their patients.

Neither this policy, nor the successful adjudication of a pharmacy claim, is guarantee of payment.                        

This program applies to Blue Partner, Commercial, GenPlus, NetResults A series, SourceRx and Health Insurance Marketplace formularies.                               

CLINICAL RATIONALE

The Affordable Care Act (ACA) requires a member-friendly mechanism for waiving the cost share for an alternative recommended product deemed medically necessary by the provider when a health care provider considers the $0 covered product is inappropriate for an individual. Prime Therapeutics offers a standard coverage exception/cost share waiver policy that is applied across all ACA categories.

https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca_implementation_faqs12.html

https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/Downloads/aca_implementation_faqs26.pdf

OBJECTIVE

The intent of the ACA Prevention Copay Waiver Criteria is to help ensure the copay waiver, when applicable based on the member's benefit, is applied to the appropriate population as described by the United States Preventative Services Task Force (USPSTF).

CLINICAL CRITERIA FOR APPROVAL

Module

Clinical Criteria for Approval

Human Immunodeficiency Virus (HIV) Infection: Pre-exposure Prophylaxis (PrEP) ACA Prevention Copay Waiver Criteria

The requested HIV infection pre-exposure prophylaxis (PrEP) agent will be approved when ALL of the following are met:

  1. The requested PrEP agent is covered under the pharmacy benefit or has been approved through the coverage exception process AND
  2. The requested agent is being used for PrEP AND
  3. There is support that the requested PrEP agent is medically necessaryAND
  4. The requested PrEP agent is ONE of the following:
    1. Tenofovir disoproxil fumarate and emtricitabine combination ingredient agent OR
    2. Tenofovir alafenamide and emtricitabine combination ingredient agent OR
    3. Cabotegravir AND
  5. The patient has increased risk for HIV infection AND
  6. The patient has recently tested negative for HIV

Length of Approval: 12 months

             

BCBSAL _  Commercial _ PS _ Copay Waiver for Human Immunodeficiency Virus (HIV) Infection: Pre-exposure Prophylaxis (PrEP) ACA Prevention Copay Waiver Criteria - Individual Marketplace, Commercial _  07-01-2024  _  © Copyright Prime Therapeutics LLC. May 2024 All Rights Reserved